These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7775960)

  • 21. Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: a 4-year follow-up of 211 patients.
    Manesis EK; Papaioannou C; Gioustozi A; Kafiri G; Koskinas J; Hadziyannis SJ
    Hepatology; 1997 Sep; 26(3):734-9. PubMed ID: 9303505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A long-term follow-up study of interferon treatment for chronic hepatitis C in Japanese patients with congenital bleeding disorders.
    Yamada M; Fukuda Y; Koyama Y; Nakano I; Urano F; Isobe K; Takamatsu J; Imoto M; Hayakawa T
    Eur J Haematol; 1996 Aug; 57(2):165-70. PubMed ID: 8856094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers.
    Okazaki T; Yoshihara H; Suzuki K; Yamada Y; Tsujimura T; Kawano K; Yamada Y; Abe H
    Scand J Gastroenterol; 1994 Nov; 29(11):1039-43. PubMed ID: 7871371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of chronic hepatitis C with interferon alpha: long-term follow-up and prognostic relevance of HCV genotypes.
    Hopf U; Berg T; König V; Küther S; Heuft HG; Lobeck H
    J Hepatol; 1996; 24(2 Suppl):67-73. PubMed ID: 8836892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genotype, viral load and age as independent predictors of treatment outcome of interferon-alpha 2a treatment in patients with chronic hepatitis C. Construct group.
    Bell H; Hellum K; Harthug S; Maeland A; Ritland S; Myrvang B; von der Lippe B; Raknerud N; Skaug K; Gutigard BG; Skjaerven R; Prescott LE; Simmonds P
    Scand J Infect Dis; 1997; 29(1):17-22. PubMed ID: 9112292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical characteristics and antibody profiles of chronic hepatitis C patients: relation to hepatitis C virus genotypes.
    Yuki N; Hayashi N; Mita E; Hagiwara H; Oshita M; Ohkawa K; Katayama K; Kasahara A; Fusamoto H; Kamada T
    J Med Virol; 1995 Feb; 45(2):162-7. PubMed ID: 7539828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus. A prospective, double-blind, randomized study.
    Villa E; Trande P; Grottola A; Buttafoco P; Rebecchi AM; Stroffolini T; Callea F; Merighi A; Camellini L; Zoboli P; Cosenza R; Miglioli L; Loria P; Iori R; Carulli N; Manenti F
    Dig Dis Sci; 1996 Jun; 41(6):1241-7. PubMed ID: 8654159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alfa.
    Tanaka E; Kiyosawa K; Matsumoto A; Kashiwakuma T; Hasegawa A; Mori H; Yanagihara O; Ohta Y
    Hepatology; 1996 Jun; 23(6):1330-3. PubMed ID: 8675147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C.
    De Rosa FG; Bargiacchi O; Audagnotto S; Garazzino S; Cariti G; Raiteri R; Di Perri G
    J Antimicrob Chemother; 2006 Feb; 57(2):360-3. PubMed ID: 16396921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinico-pathological predictive factors of response to interferon therapy in chronic hepatitis C.
    Thavarungkul P; Toriyama K; Kusuda M; Kamito H; Kamito M; Nakayama T; Kato Y; Itakura H
    Southeast Asian J Trop Med Public Health; 1996 Mar; 27(1):85-90. PubMed ID: 9031407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa.
    Zeuzem S; Lee JH; Roth WK
    Hepatology; 1997 Mar; 25(3):740-4. PubMed ID: 9049228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection.
    Weiland O; Chen M; Lindh G; Mattsson L; Schvarcz R; Sönnerborg A; Wahl M; Wejstål R; Widell A; Norkrans G
    Scand J Infect Dis; 1995; 27(4):319-24. PubMed ID: 8658063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of hepatitis C viral sequences in formalin-fixed, paraffin-embedded liver tissue: effect of interferon alpha therapy.
    Diamond DA; Davis GL; Qian KP; Lau JY
    J Med Virol; 1994 Mar; 42(3):294-8. PubMed ID: 8006643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatic expression of hepatitis C virus RNA in chronic hepatitis C: a study by in situ reverse-transcription polymerase chain reaction.
    Lau GK; Davis GL; Wu SP; Gish RG; Balart LA; Lau JY
    Hepatology; 1996 Jun; 23(6):1318-23. PubMed ID: 8675145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic hepatitis C: the viral load per liver cell before treatment as a new marker to predict long-term response to IFN-alpha therapy.
    Schlaak JF; Trippler M; Ernst I; Meyer zum Büschenfelde KH; Gerken G
    J Hepatol; 1997 Nov; 27(5):917-21. PubMed ID: 9382981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prognostic relevance of hepatitis C virus genotype for responsiveness to interferon-alpha].
    Berg T; König V; Küther S; Heuft HG; Wittmann G; Lobeck H; Hopf U
    Z Gastroenterol; 1995 Aug; 33(8):426-30. PubMed ID: 7483733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C.
    Shiffman ML; Hofmann CM; Thompson EB; Ferreira-Gonzalez A; Contos MJ; Koshy A; Luketic VA; Sanyal AJ; Mills AS; Garrett CT
    Hepatology; 1997 Sep; 26(3):780-5. PubMed ID: 9303513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.
    Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M
    J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sustained negativity for HCV-RNA over 24 or more months by long-term interferon therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load.
    Arase Y; Suzuki F; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Kobayashi M; Sezaki H; Ikeda K; Kumada H
    Intervirology; 2004; 47(1):19-25. PubMed ID: 15044832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of chronic hepatitis C infection with interferon alpha-2a in a Turkish population.
    Simsek H; Tatar G; Savas C; Telatar H
    J Int Med Res; 1996; 24(1):132-7. PubMed ID: 8674791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.